Science by AmbushApril 2013
By William Faloon
Cardiologists Only Partially Correct Atherogenic Risk Factors
Prescribing a statin drug is what doctors typically do to prevent and treat coronary atherosclerosis. Cholesterol and LDL, however, are only two players in the atherosclerosis process.
There are now two fish oil “drugs” approved by the FDA to lower triglycerides. Fish oil also protects against atherosclerosis by reducing inflammation63-71 and inhibiting abnormal platelet aggregation.72-76 But even fish oil and statin drugs are not going to adequately counteract all factors involved in coronary artery disease.
Mainstream cardiologists fail to appreciate that coronary atherosclerosis is a sign of systemic arterial dysfunction requiring aggressive therapy to correct.
To read more about the steps you need to take to reduce your odds of being stricken with a vascular disorder, refer to the articles on pages 68 and 78 of this month’s issue.
How We Protect You
Life Extension’s annual Blood Test Super Sale commences April 1, 2013. The reason I am alerting you early is to enable you to start preparing for your annual comprehensive blood tests.
Make sure, for example, that you take your omega-3 and vitamin D supplements with the heaviest meal of the day. These fat-soluble nutrients absorb far better when consumed with the meal of the day that contains the most fat. A problem we fear occurs in clinical studies is that participants take fat-soluble nutrients on relatively empty stomachs, which leads to poor absorption and subsequent failure to derive benefits.
The extensive focus group sessions we conducted reveal the typical consumer has no idea what they need to do to protect against the degenerative diseases of aging.
We provide our members with every means of support possible, from access to knowledgeable health advisors and low-cost comprehensive blood testing, to accurately reported scientific data and ongoing clinical research.
The public, on the other hand, is left to rely on a sound-bite frenzied news media for health data, which often involves flouting a scary medical headline without assessing a story’s veracity. I call this science by ambush because it blind sides an established principle, and denies an opportunity for meaningful rebuttal!
For longer life,
- Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012 Sep 12;308(10):1024-33.
- Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/heart-disease-risk-reduction/. Accessed January 15, 2013.
- Chang CY, Ke DS, Chen JY. Essential fatty acids and human brain. Acta Neurol Taiwan. 2009 Dec;18(4):231-41.
- Available at: http://www.usatoday.com/news/health/story/2012-09-11/heart-omega-3/57750182/1. Accessed December 3, 2012.
- Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival. Cardiovasc Drugs Ther. 1997;11(3):485-91.
- Yokoyama M, Origasa H, Matsuzawa M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8.
- Svensson M, Schmidt EB, Jørgensen KA, et al. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol. 2006 Jul;1(4):780-6.
- von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130(7):554-62.
- Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20(8):1493-9.
- Schiano V, Laurenzano E, Brevetti G, et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008 Apr;27(2):241-7.
- Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23;105(16):1897-903.
- Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909229/. Accessed January 15, 2013.
- Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757-61.
- Zhao YT, Chen Q, Sun YX, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary artery disease: a meta-analysis of randomized controlled trials. Ann Med. 2009;41(4):301-10.
- Marik PE and Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365-72.
- León H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.
- Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112(4):298-304.
- Piechota W, Piechota W. Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease. Pol Merkur Lekarski. 2005 May;18(107):511-5.
- Choi EY, Yan RT, Fernandes VR, et al. High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis. Am Heart J. 2012 Aug;164(2):251-8.
- Van Der Meer IM, De Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002 Dec;33(12):2750-5.
- Masood A, Jafar SS, Akram Z. Serum high sensitivity C-reactive protein levels and the severity of coronary atherosclerosis assessed by angiographic gensini score. J Pak Med Assoc. 2011 Apr;61(4):325-7.
- Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.
- Auer J, Berent R, Lassnig E, Eber B. C-reactive protein and coronary artery disease. Jpn Heart J. 2002 Nov;43(6): 607-19.
- Agmon Y, Khandheria BK, Meissner I, et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med. 2004 Sep 13;164(16):1781-7.
- Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481-5.
- Jarosz A, Nowicka G. C-reactive protein and homocysteine as risk factors of atherosclerosis. Przegl Lek. 2008 65(6): 268-72.
- Bonora E, Kiechl S, Willeit J, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007 Feb;30(2):318-24.
- Sundell J, Luotolahti M. Association between insulin resistance and reduced coronary vasoreactivity in healthy subjects. Can J Cardiol. 2004 May 15;20(7):691-5.
- Stochmal E, Szurkowska M, Czarnecka D, et al. Association of coronary atherosclerosis with insulin resistance in patients with impaired glucose tolerance. Acta Cardiol. 2005 Jun;60(3):325-31.
- Takahashi F, Hasebe N, Kawashima E, et al. Hyperinsulinemia is an independent predictor for complex atherosclerotic lesion of thoracic aorta in non-diabetic patients. Atherosclerosis. 2006 Aug;187(2):336-42.
- Stout RW. The relationship of abnormal circulating insulin levels to atherosclerosis. Atherosclerosis. 1977 May;27(1):1-13.
- Chien KL, Lee YT, Sung FC, Hsu HC, Su TC, Lin RS. Hyperinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: a community-based study. Clin Chem. 1999 Jun;45(6 Pt 1):838-46.
- Howes PS, Zacharski LR, Sullivan J, Chow B. Role of stored iron in atherosclerosis. J Vasc Nurs. 2000 Dec;18(4):109-14; quiz 115-6.
- Chau LY. Iron and atherosclerosis. Proc Natl Sci Counc Repub China B. 2000 Oct;24(4):151-5.
- Kraml P, Potockova J, Koprivova H, et al. Ferritin, oxidative stress and coronary atherosclerosis. Vnitr Lek. 2004 Mar;50(3):197-202.
- Minqin R, Watt F, Huat BT, Halliwell B. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic Biol Med. 2003 Mar 15;34(6):746-52.
- Montalcini T, Gorgone G, Federico D, et al. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2005 Oct;15(5):368-72.
- Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1071-80.
- Reed DM, Strong JP, Resch J, Hayashi T. Serum lipids and lipoproteins as predictors of atherosclerosis. An autopsy study. Arteriosclerosis. 1989 Jul-Aug;9(4):560-4.
- Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004 Sep;6(5):381-7.
- Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol. 1997 Jun;13(6):591.
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
- Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005 Jul;181(1):159-65.
- Montalescot G, Ankri A, Chadefaux-Vekemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol. 1997 Aug 8;60(3):295-300.
- Fernández-Miranda C, Paz M, Aranda JL, et al. Homocysteine and progression of carotid atherosclerosis in patients with coronary disease. Med Clin (Barc). 2003 Nov 1;121(15):561-4.
- Cacciapuoti F. Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors. Blood Coagul Fibrinolysis. 2012 Dec;23(8):677-9
- Liu MY, Hu DY. The predictive value of serum advanced fibrinogen and uric acid for acute coronary event risk. Zhonghua Yi Xue Za Zhi. 2006 Mar 14;86(10):678-80.
- Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC)study. Am Heart J. 2005 Apr;149(4):606-12.
- Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1368-77.
- Acevedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J. 2002 Feb;143(2): 277-82.
- Drexel H, Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994 Nov;90(5):2230-5.
- Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16.
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298(3):299-308.
- Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999 Nov 1;147(1):133-8.
- Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol. 2003 Jul;18(4):286-94.
- Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002 Mar 26;105(12):1399-402.
- Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.
- English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 Jun;21(11):890-4.
- Tivesten A, Mellström D, Jutberger H, et al. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol. 2007 Sep 11;50(11):1070-6.
- Dunajska K, Milewicz A, Szymczak J, et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male. 2004 Sep;7(3):197-204.
- Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994 May;14(5):701-6.
- Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005;5(3): 141-54.
- Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun. 2012 Aug;26(6):988-95.
- Wu D, Han SN, Meydani M, Meydani SN. Effect of concomitant consumption of fish oil and vitamin E on production of inflammatory cytokines in healthy elderly humans. Ann NY Acad Sci. 2004 Dec;1031:422-4.
- Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003 Jul 15;108(2):155-60.
- Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004 Nov;6(6):461-7.
- James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000 Jan;71(1 Suppl): 343S-8S.
- Adam O, Beringer C, Kless T, et al. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol Int. 2003 Jan;23(1):27-36.
- Lopez-Garcia E, Schulze MB, Manson JE, et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004 Jul;134(7): 1806-11.
- Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: A randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl. 1989;225(731): 225-32.
- Foitzik T, Eibl G, Schneider P, Wenger FA, Jacobi CA, Buhr HJ. Omega-3 fatty acid supplementation increases anti-inflammato ry cytokines and attenuates systemic disease sequelae in experimental pancreatitis. J Parenter Enteral Nutr. 2002 Nov-Dec;26(6):351-6.
- Nomura S, Kanazawa S, Fukuhara S. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus. J Diabetes Complications. 2003 May-Jun;17(3):153-9.
- Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997 Feb;17(2):279-86.
- Abeywardena MY, Head RJ. Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res. 2001 Dec;52(3):361-71.
- Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet. 1981 Nov 28;2(8257):1190-3.
- Vanschoonbeek K, Feijge MAH, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol. 2004 Sept;24(9):1734–40.